This test is used as a companion diagnostic to determine which patients with metastatic NSCLC are eligible for first-line, maintenance, or second-line treatment with erlotinib, an EGFR-targeted medication [808]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.